$RDTCF $DOSE.CN Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory
https://www.newsfilecorp.com/release/290053/R...Trajectory
Burlington, Ontario--(Newsfile Corp. - March 26, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"
, a Canadian biotechnology leader specializing in innovative oral thin film drug delivery, is pleased to provide shareholders with a strategic update highlighting its continued execution, operational resilience, and expanding global footprint.
In an environment marked by global market volatility and geopolitical uncertainty, RDT is uniquely positioned with a business model that remains largely insulated from external disruptions. The Company's operations are not dependent on oil-linked inputs or global shipping constraints, and its cost structure is primarily composed of stable, fixed components. This positioning enables RDT to maintain operational continuity and focus squarely on long-term value creation.
Since the beginning of 2026, RDT has achieved several meaningful milestones that further de-risk its growth strategy and strengthen its position across key international markets.
Key Strategic Developments
Global Intellectual Property Expansion – India Patent Grant
RDT, alongside its partner Aavishkar Oral Strips Pvt. Ltd., has secured a significant patent (IN 582202) from the Indian Patent Office for its Nicotine Bilayer Oral Film. This achievement enhances the Company's intellectual property portfolio within one of the world's fastest-growing nicotine alternative markets and reinforces its broader global IP strategy under the Patent Cooperation Treaty framework with potential protection across 158 jurisdictions worldwide. Link: Newsfile.
Advancing Global Tobacco Collaboration
The Company continues to build momentum in its fourth year of collaboration with a major global tobacco partner. Ongoing pharmacokinetic (PK) trials are designed to demonstrate that RDT's QuickStrip™ nicotine formulation can replicate the rapid absorption profile of traditional cigarettes—delivering effective craving management without the harmful effects of combustion. Link: RDT.
Expansion into Brazil's Healthcare Market
Following regulatory approval from ANVISA, RDT has successfully launched its QuickStrip™ medical cannabis product in Brazil unlocking access to one of the largest pharmaceutical and healthcare markets in Latin America. This milestone highlights the Company's ability to navigate regulatory frameworks and expand into high-growth international markets
Enhanced U.S. Market Presence
RDT's recent listing on the OTCQB Venture Market under the symbol RDTCF marks a significant step in expanding U.S. investor access, improving liquidity, and increasing overall market visibility. Link: Newsfile.
Clinical Validation and Research Progress
The Company continues to advance its clinical research initiatives, including a CBD bioavailability study conducted in collaboration with the University of Regina and the University of Saskatchewan. Supported by research funding from the National Football League (NFL), the study has already generated data from over 60% of participants, further supporting the efficacy and potential of the QuickStrip™ platform. Link: Newsfile.
2026 Strategic Priorities
RDT remains focused on executing key growth initiatives, including:
Expanding into regulated international markets through strategic partnerships
Strengthening distribution channels for natural health products
Advancing clinical research and validation across multiple verticals
Scaling and securing regulatory approval for Canadian manufacturing capabilities, including pharmaceutical-grade production
These initiatives collectively position RDT to capitalize on opportunities across pharmaceutical, nutraceutical, nicotine, and wellness sectors.
Leadership Commentary
"Our momentum in 2026 reflects the strength of our strategy and the scalability of the QuickStrip™ platform," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "With a resilient operating model and continued progress across IP, clinical development, and global markets, RDT is well insulated from current macroeconomic pressures and exceptionally well positioned to deliver sustainable, long-term value for our shareholders."
https://www.newsfilecorp.com/release/290053/R...Trajectory
Burlington, Ontario--(Newsfile Corp. - March 26, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"
, a Canadian biotechnology leader specializing in innovative oral thin film drug delivery, is pleased to provide shareholders with a strategic update highlighting its continued execution, operational resilience, and expanding global footprint. In an environment marked by global market volatility and geopolitical uncertainty, RDT is uniquely positioned with a business model that remains largely insulated from external disruptions. The Company's operations are not dependent on oil-linked inputs or global shipping constraints, and its cost structure is primarily composed of stable, fixed components. This positioning enables RDT to maintain operational continuity and focus squarely on long-term value creation.
Since the beginning of 2026, RDT has achieved several meaningful milestones that further de-risk its growth strategy and strengthen its position across key international markets.
Key Strategic Developments
Global Intellectual Property Expansion – India Patent Grant
RDT, alongside its partner Aavishkar Oral Strips Pvt. Ltd., has secured a significant patent (IN 582202) from the Indian Patent Office for its Nicotine Bilayer Oral Film. This achievement enhances the Company's intellectual property portfolio within one of the world's fastest-growing nicotine alternative markets and reinforces its broader global IP strategy under the Patent Cooperation Treaty framework with potential protection across 158 jurisdictions worldwide. Link: Newsfile.
Advancing Global Tobacco Collaboration
The Company continues to build momentum in its fourth year of collaboration with a major global tobacco partner. Ongoing pharmacokinetic (PK) trials are designed to demonstrate that RDT's QuickStrip™ nicotine formulation can replicate the rapid absorption profile of traditional cigarettes—delivering effective craving management without the harmful effects of combustion. Link: RDT.
Expansion into Brazil's Healthcare Market
Following regulatory approval from ANVISA, RDT has successfully launched its QuickStrip™ medical cannabis product in Brazil unlocking access to one of the largest pharmaceutical and healthcare markets in Latin America. This milestone highlights the Company's ability to navigate regulatory frameworks and expand into high-growth international markets
Enhanced U.S. Market Presence
RDT's recent listing on the OTCQB Venture Market under the symbol RDTCF marks a significant step in expanding U.S. investor access, improving liquidity, and increasing overall market visibility. Link: Newsfile.
Clinical Validation and Research Progress
The Company continues to advance its clinical research initiatives, including a CBD bioavailability study conducted in collaboration with the University of Regina and the University of Saskatchewan. Supported by research funding from the National Football League (NFL), the study has already generated data from over 60% of participants, further supporting the efficacy and potential of the QuickStrip™ platform. Link: Newsfile.
2026 Strategic Priorities
RDT remains focused on executing key growth initiatives, including:
Expanding into regulated international markets through strategic partnerships
Strengthening distribution channels for natural health products
Advancing clinical research and validation across multiple verticals
Scaling and securing regulatory approval for Canadian manufacturing capabilities, including pharmaceutical-grade production
These initiatives collectively position RDT to capitalize on opportunities across pharmaceutical, nutraceutical, nicotine, and wellness sectors.
Leadership Commentary
"Our momentum in 2026 reflects the strength of our strategy and the scalability of the QuickStrip™ platform," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "With a resilient operating model and continued progress across IP, clinical development, and global markets, RDT is well insulated from current macroeconomic pressures and exceptionally well positioned to deliver sustainable, long-term value for our shareholders."
